Summary
Overview
Work History
Education
Skills
Teaching Responsibilities
Certification
Grant Support
Clinical Positions
Academic Positions
Timeline
Generic

William T Sypula

Novi,MI

Summary

Experienced leader in Medical Affairs with a proven track record of successfully managing and guiding teams of Medical Science Liaisons. Strategic and results-driven, with expertise in developing and aligning U.S. Medical Strategies with Global initiatives. Skilled in building strong relationships with matrix and external partners, leading to effective collaborations and achievements in the medical field. Strong accomplishments include team expansion during challenging times, launching groundbreaking treatments, and implementing innovative programs to enhance medical science liaison effectiveness. Recognized for developing successful collaborations with CRO and CRA partners, resulting in improved investigator relationships and study completion ahead of deadlines.

Overview

24
24
years of professional experience
1
1
Certification

Work History

Regional Director USMA – East Region

Leo Pharmaceuticals
09.2019 - Current
  • Led and managed the performance of a team of 7 Medical Science Liaisons within the East Region
  • Provide strategic leadership to leverage the MSLs scientific and clinical expertise to ensure mutually agreeable interactions with scientific experts in a compliant manner
  • Build and maintain strong working relationships with internal and external business partners specific to the therapeutic area
  • Develop U.S Medical Strategy aligned with Global initiatives in support of U.S Clinical Development and Commercial Strategy for Actinic Keratosis, Psoriasis, Rosacea & Atopic Dermatitis therapeutic areas
  • Co-Lead and development the investigator-initiated study program (IIS) at LEO with successful implementation and publication of 10 IISs to guide medical strategies for future Phase 3 programs
  • Medical Affairs Leadership and Achievement
  • Built a team of 15 MSLs from 8 within a 6-month time frame during height of COVID-19
  • Launched first ever biologic targeting IL-13 for the treatment of atopic dermatitis
  • Implemented Executive Medical Science Liaison Program at LEO & developed 2 MSLs from Senior MSL to Executive MSL and 4 MSLs to Senior MSL
  • Developed/Implemented MSL-CRA Collaboration Program to establish working relationship with CRO & CRA partners to strengthen investigator relationships/enrollment that led to completing 4 studies ahead of deadlines.

Senior Medical Liaison Science– Regulatory

LEO Pharmaceuticals Inc.
02.2012 - 09.2019
  • Recognized expert the field of psoriasis, atopic dermatitis, and actinic keratosis
  • Maintained a 7-state territory that supports Dermatology key opinion leaders and supported cross-molecule functions in terms of IST’s, continuing education, and field-based support
  • Disseminated scientific information regarding Leo Products: - Taclonex (calcipotriene/betamethasone) Picato (ingenol mebutate) from unsolicited requests for the treatment of psoriasis and actinic keratosis
  • Supported ongoing clinical trials within Leo Pharmaceuticals with respect to education and clinical support
  • Lead MSL for the Tralokinumab anti-IL13 program for Atopic Dermatitis
  • Maintained active professional advancement activities in mentorship, leadership, and ongoing educational opportunities
  • Attended and participate in necessary medical/scientific meetings in dermatology, hematology/oncology, and various disciplines that treat psoriasis or actinic keratosis
  • Supported Commercial activities at Plan of Action meetings, MSL unsolicited requests and educational events.

Medical Science Liaison II – Feraheme (ferumoxytol Injection)

AMAG Pharmaceuticals
11.2009 - 12.2011
  • Recognized expert in the field of iron deficiency anemia and chronic kidney disease
  • Disseminated scientific information about Feraheme, (ferumoxytol injection) from unsolicited for the treatment of iron deficiency anemia as it relates to the chronic kidney disease patient
  • Supported ongoing clinical trials within AMAG Pharmaceuticals with respect to education and clinical support
  • Maintained a 4-state territory that supports Nephrology and hematology/oncology key opinion leaders in their respected fields
  • Supported cross-molecule functions in terms of IST’s, continuing education, and field-based support
  • Maintained active professional advancement activities in mentorship, leadership, and ongoing educational opportunities
  • Attended and participated in necessary medical/scientific meetings in nephrology, hematology/oncology, and various disciplines that treat iron deficiency anemia
  • Supported Commercial activities at Plan of Action meetings, MSL unsolicited requests, and educational events.

Medical Science Liaison II – Clinical Development: Raptiva/Telbermin

Genentech Inc.
09.2007 - 10.2009
  • Recognized as an efalizumab / biologic therapeutic expert in the treatment of moderate to severe psoriasis
  • Disseminated scientific information about efalizumab, a monoclonal antibody, through unsolicited requests by healthcare professionals
  • Maintained a territory of 12 states and developed relationships with key opinion leaders in the field of dermatology and transplant medicine
  • Supported and presented Investigator initiated trials in psoriasis, autoimmune diseases, and transplant medicine to the Clinical Trials Review Committee (CTRC) at Genentech
  • Prepared principal investigators on IRB, FDA, and budgetary submissions as it relates to their IST submission packets
  • Attended and participated in necessary medical/scientific meetings in the dermatology and transplant fields: (American Academy of Dermatology, American Transplant Society, Winter Clinical Dermatology)
  • Supported Genentech’s Phase 4 clinical programs (Scalp Trial, Anti-TNF, Response and Follow Registry)
  • Attended and presented scientific information at Raptiva Scientific Advisory Board meetings
  • Supported cross-molecule functions in terms of IST’s, continuing education, and field-based support
  • Maintained active professional advancement activities in mentorship, leadership, and ongoing educational opportunities.

Senior Medical Science Liaison – Midwest Region

Intermune, Inc
06.2006 - 04.2007
  • Recognized as a therapeutic expert in the field of Idiopathic Pulmonary Fibrosis
  • Managed 7 states in the Midwest territory and developed over 50 key opinion leaders in the field of pulmonology and pulmonary pathology
  • Disseminated scientific information on Actimmune (interferon gamma 1b) in preparation of the final results of the INSPIRE Trial
  • Anticipated May 2007
  • Supported principal investigators for the INSPIRE Trial and activities associated with the trial
  • Disseminated scientific information on Pirfenidone, a small molecule weight peptide which exhibits anti-fibrotic activity through the P38 kinase pathway
  • Supported the CAPACITY Trial (Pirfenidone for IPF) initiatives and provided principal investigators with ongoing trial support though Capacity Trial Awareness Programs to raise awareness of the trial to local and regional pulmonologists
  • Participated and supported Intermune at appropriate medical conferences (CHEST, ATS) as well as local and regional pulmonary meetings
  • Supported PILOT initiatives – (Pulmonary Fibrosis Identification: Lessons for Optimizing Treatment) a national education initiative designed to provide physicians with a comprehensive continuing medical education program that focuses on the early and accurate diagnosis of idiopathic pulmonary fibrosis (IPF) while addressing educational objectives critical to optimizing disease intervention and management.

Senior/Interim Manager- Medical Science Liaison – U.S. Medical Affairs

Discovery Laboratories Inc.
12.2005 - 04.2006
  • Recognized as a therapeutic expert in the field of pulmonary surfactant replacement therapy in the treatment of Respiratory Distress Syndrome in premature infants
  • Lucinactant (Surfaxin) is a synthetic pulmonary surfactant replacement therapy containing phospholipids (DPPC, POPG, and palmitic acid (PA)) with sinapultide (KL4) added to provide the necessary SP-B protein
  • This compound is also being studied in a aerosolized version (Aerosurf) for the treatment of other pulmonary diseases
  • Disseminated scientific information related to the development of Lucinactant (Surfaxin) and KL4 compound to key opinion leaders and institutions within the MI, OH, IN, TN, KY, WV, PA and NY territories
  • Maintained and developed 65 institutions on lucinactant and Aerosurf with future clinical trials relating to Acute Respiratory Distress Syndrome (ARDS), Chronic Lung Disease (CLD), Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
  • Managed 11 MSL’s across the USA plus own territory with respect to policies and procedures set forth by the Medical Affairs Department at Discovery Labs
  • Prepared pre-launch activities with respect to lucinactant (Surfaxin) and aerosolized lucinactant (Aerosurf)
  • Prepared and developed KOL’s and institutions on Phase 2 & Phase 3 clinical trials (BP Aerosurf) with respect to lucinactant (Surfaxin) and aerosolized lucinactant (Aerosurf)
  • Attended and presented at necessary scientific advisory boards regarding clinical and future clinical trial
  • Participated at relevant local, state, and national scientific meetings relating to neonatal and adult pulmonary critical care issues.

Regional Medical Liaison – U.S. Medical Affairs

Sanofi-Aventis Pharmaceuticals
07.2003 - 11.2005
  • Recognized as a therapeutic expert in Diabetes and Diabetes disease management and pharmacologic treatments available to prescribers as it relates to diabetes and diabetes disease management
  • Cultivated and maintain relationships with key thought leaders and advocates focusing on educational updates and research opportunities
  • Participated as a scientific resource for internal groups, including medical informatics scientists and marketing
  • Facilitated educational events (one-on-ones, presentations, etc.) with external health care professionals and/or internal customers
  • (Avg 80/quarter)
  • Respond to requests for scientific and product information on investigational and marketed products
  • Facilitated the provision of Regional and Local Consultant Panel Meetings
  • Maintained appropriate relationships with Regional Account Managers and National Managed care accounts
  • Facilitated quarterly training sessions in collaboration with the other regional trainers and product leads
  • Worked in collaboration with NEST on field initiatives
  • Identified appropriate sites for specific protocols in conjunction with the Clinical Research Associates
  • Utilized funds to assist regionally based educational endeavors
  • Worked with Managed Care/Health Outcomes Departments with assistance in study preparation
  • Collaborated with National Medical Managers, Federal Account Managers, and Governmental Account Managers - provide scientific information to governmental & Veteran’s Administration Hospitals.

Assistant Professor of Pharmacy Practice (Clinical)

Wayne State University/Henry Ford Health System
08.2000 - 01.2003
  • Primary clinical teaching (8 hours/week) responsibilities in the areas of internal medicine, infectious diseases, pediatrics with sub-specialties in pharmacokinetics and clinical trial design.

Education

Doctor of Pharmacy (Pharm.D.) - Pharmacy

Wayne State University, College of Pharmacy
Detroit, MI
05.2000

Bachelor of Science in Pharmacy (B.S.Pharm) -

Wayne State University Eugene Applebaum College of Pharmacy And Health Sciences
Detroit, MI
05.1990

Skills

  • Key External Expert Relationships
  • Medical Affairs Leadership
  • MSL Recruitment, Training and Professional Development
  • Matrix Team Relationship Building

Teaching Responsibilities

  • PPR 6260: Advanced Problem-Solving, Section Coordinator/Lecturer, 60
  • PHA 4120 Gastroenterology/Nutrition, Lecturer, 2
  • PHA 4240: Principles of Pharmacotherapy-IV Special Patient Populations, Module Coordinator/Lecturer, 16
  • PPR 5120: Undergraduate Externship, Clerkship Coordinator, 12
  • PPR 5100: Orientation to Externship, Lecturer, 3
  • Resident Lecture Series, Lecturer
  • Longitudinal Advanced Practice Program, Program Coordinator, 2nd year

Certification

  • 1990 - Present, Registered Pharmacist, Michigan, 5302027195
  • 2002 - 2008, Board Certified Pharmacotherapy Specialist (BCPS), American College of Clinical Pharmacy (ACCP)
  • 2002 - 2003, Pediatric Advanced Life Support (PALS)
  • 1998 - 2004, Advanced Cardiac Life Support (ACLS)

Grant Support

  • DVT FREE. An Epidemiological Observational Study of Deep Venous Thrombosis (DVT)., Genecom Corp, $10,000, 2002, Principal Investigator
  • Unrestricted educational grant, Aventis Pharmaceuticals, $5,000, 2002

Clinical Positions

  • 08/1990, 08/2000, Staff Clinical Pharmacist, Children’s Hospital of Michigan, 3901 Beaubien, Detroit, MI, 48201, Compounded and Dispensed medicines and related articles, order entry, computerized unit dose, IV admixture as related to neonatal and pediatric patients., Major emphasis on the Pharmacokinetic Dosing Service, O.R. Satellite, Pediatric Nutritional Support Team, Pediatric Intensive Care Unit, Neonatal Intensive Unit and Drug Information Center., Duties included work with the General Surgery Service, Adolescent Medicine, Neurosurgical Team and the Department of Nephrology.
  • 11/1995, 1998, Staff Clinical Pharmacist, Botsford General Hospital, 28050 Grand River Ave., Farmington Hills, MI, 48336, Primary activities included the Pharmacokinetic Dosing Service in ICU, CCU, ACU, surgical and general medical floors., Duties also included participation on the Pain Management Team with emphasis on PCA dosing and monitoring., Participation on the hospital’s Pediatrics Committee which regulated the use of pharmaceuticals within the pediatric floor., Other duties included work in the Hematology/Oncology Satellite, order entry, unit dose, IV admixture, and drug product selection.
  • 02/1989, 1990, Pharmacy Intern, Children’s Hospital of Michigan, 3901 Beaubien, Detroit, MI, 48201

Academic Positions

08/2000, 2003, Assistant Professor of Pharmacy Practice (Clinical), Wayne State University/Henry Ford Health System, 258 Mack Ave., Detroit, MI, 48201, Primary clinical teaching (8 hours/week) responsibilities in the areas of internal medicine, infectious diseases, pediatrics with sub-specialties in pharmacokinetics and clinical trial design.

Timeline

Regional Director USMA – East Region

Leo Pharmaceuticals
09.2019 - Current

Senior Medical Liaison Science– Regulatory

LEO Pharmaceuticals Inc.
02.2012 - 09.2019

Medical Science Liaison II – Feraheme (ferumoxytol Injection)

AMAG Pharmaceuticals
11.2009 - 12.2011

Medical Science Liaison II – Clinical Development: Raptiva/Telbermin

Genentech Inc.
09.2007 - 10.2009

Senior Medical Science Liaison – Midwest Region

Intermune, Inc
06.2006 - 04.2007

Senior/Interim Manager- Medical Science Liaison – U.S. Medical Affairs

Discovery Laboratories Inc.
12.2005 - 04.2006

Regional Medical Liaison – U.S. Medical Affairs

Sanofi-Aventis Pharmaceuticals
07.2003 - 11.2005

Assistant Professor of Pharmacy Practice (Clinical)

Wayne State University/Henry Ford Health System
08.2000 - 01.2003

Doctor of Pharmacy (Pharm.D.) - Pharmacy

Wayne State University, College of Pharmacy

Bachelor of Science in Pharmacy (B.S.Pharm) -

Wayne State University Eugene Applebaum College of Pharmacy And Health Sciences

Similar Profiles

CREATE PROFILE
William T Sypula